Company intelligence / Profile preview
Thabor Therapeutics
Paris, Île-de-France, Francethabor-tx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Thabor Therapeutics, an INSERM spin-off based in Paris, France, develops a first-in-class therapeutic antibody targeting extracellular AGR2 for the treatment of chronic mucosal inflammatory diseases. Their approach aims to reinstate epithelial homeostasis by blocking the initial stress signal from the epithelium, thereby preventing inflammation and fibrosis without immunosuppression. The company’s lead program appears preclinical with no reported clinical results yet.
- Therapeutic areas
- Immunology
- Modalities
- monoclonal antibodies (therapeutic antibody)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
INSERM (spin-off origin); no major pharma partnerships disclosed
Beyond the preview
Go deeper on Thabor Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thabor Therapeutics.